Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

51
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
51
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

26
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

62
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
62
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

31
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
31
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

851
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
851

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automated Identification of Surgical Site Infections From Electronic Medical Records: Retrospective Observational Predictive Modeling Study.

JMIR perioperative medicine·2026
Same author

Designing Emotion-Integrated Visualizations for Kidney Function Self-Management: User-Centered Design Study With Youth Transplant Recipients and Caregivers.

Journal of medical Internet research·2026
Same author

Nonmedical Gender-Affirming Supports and Resources Most Desired by Transgender and Non-Binary Adolescents.

Transgender health·2026
Same author

My Kidney T.R.E.K. - Thinking, Reflecting, and Empowering Kidney Transplant Patients, through technology.

AMIA ... Annual Symposium proceedings. AMIA Symposium·2026
Same author

Enhancing Health Research Results Dissemination for American Indian and Alaska Native Communities through Indigenous Community-Centered Design.

AMIA ... Annual Symposium proceedings. AMIA Symposium·2026
Same author

Mitigating Stigma and Fostering Support: Improving AI-Generated Counterspeech for Microaggressions.

AMIA ... Annual Symposium proceedings. AMIA Symposium·2026

Related Experiment Video

Updated: Feb 24, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

Design Recommendations for Pharmacogenomics Clinical Decision Support Systems.

Maher Khelifi1, Peter Tarczy-Hornoch1, Emily B Devine1

  • 1University of Washington, Seattle, WA, USA.

AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science
|August 18, 2017
PubMed
Summary

Pharmacogenomics Clinical Decision Support Systems (PGx-CDS) face implementation challenges. This study proposes a new design approach and guidelines to improve PGx-CDS adoption for safer medication prescribing.

More Related Videos

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

716
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.9K

Related Experiment Videos

Last Updated: Feb 24, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K
Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

716
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.9K

Area of Science:

  • Clinical Informatics
  • Pharmacogenomics
  • Health Systems Research

Background:

  • Pharmacogenomics (PGx) integration into clinical practice is hindered by implementation challenges.
  • Pharmacogenomics Clinical Decision Support Systems (PGx-CDS) are crucial for translating genetic information into targeted drug therapy.
  • New guidelines emphasize genetics for optimizing drug dosage and minimizing adverse events, increasing the need for effective PGx-CDS.

Purpose of the Study:

  • To identify barriers to PGx-CDS implementation in clinical settings.
  • To develop an innovative design approach for PGx-CDS with enhanced functional characteristics.
  • To establish design guidelines and recommendations for effective PGx-CDS tools to improve patient safety.

Main Methods:

  • Systematic review and analysis of existing PGx-CDS implementation barriers.
  • Development of a novel PGx-CDS design framework based on identified challenges.
  • Formulation of actionable design guidelines and best practices for PGx-CDS development and deployment.

Main Results:

  • Key challenges in PGx-CDS adoption include workflow integration, data interpretation, and clinician usability.
  • The proposed design approach incorporates features for improved guideline adherence and clinical decision-making.
  • Design recommendations focus on enhancing user experience, data visualization, and seamless EHR integration.

Conclusions:

  • Effective PGx-CDS design is essential for overcoming pharmacogenomics implementation barriers.
  • The developed design approach and guidelines can facilitate the broader adoption of PGx in routine clinical care.
  • Improving PGx-CDS functionality and usability will enhance patient safety and optimize drug therapy outcomes.